Article Text

PDF
PS-002 Importance of pharmacovigilance for maintaining hospital protocols including highly complex drugs: our own EGFR-TKI affair
  1. D Marquez-Medina1,
  2. M Gilabert-Sotoca2,
  3. N Pons-Llobet2,
  4. I Mangues-Bafalluy2,
  5. M Martinez Sogués2,
  6. J Schoenenbreger-Arnáiz2
  1. 1Hospital Arnau de Vilanova, Medical Oncology, Lleida, Spain
  2. 2Hospital Arnau de Vilanova, Pharmacy, Lleida, Spain

Abstract

Background Two reversible tyrosine-kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) (A and B) were approved for the treatment of EGFR-mutant advanced non-small cell lung cancer (aNSCLC), with similar activity and results. Pharmacovigilance detected efficacy differences between A and B in our centre.

Purpose To define and possibly correct the cause of this finding.

Material and methods Drug A was considered our standard treatment for EGFR-mutant aNSCLC from April 2011 to March 2013, and was replaced with B from April 2013 to the present. EGFR-mutant patients were sequentially diagnosed in two different external platforms (PA and PB) during the same periods of time. We retrospectively reviewed the medical charts of TKI-treated EGFR-mutant aNSCLC patients from April 2011 to March 2014. Progression free survival (PFS) was analysed in any, first, and second line of treatment by Kaplan-Meier curves and Cox regression. The finding of significant differences in PFS between A and B led to the retrospective review of all EGFR-analysed aNSCLC patients.

Results Fifteen EGFR-mutant aNSCLC patients were treated with A (7 s line), and 16 with B (10 s line). Mean age of the series was 65 years (44–82), and 74.2% were women. PFS benefited A in any (11.43 vs. 4.96 months; p = 0.000), first (13.3 vs. 3.98 months; p = 0.014), and second line of treatment (9.5 vs. 5.53 months; p = 0.023). PA analysed 108 aNSCLC, patients detecting 12.1% EGFR-mutant and 15% non-analysable tissue samples. PB analysed 85 aNSCLC, patients finding 20% EGFR-mutant and 3.5% non-analysable tissue samples.

Conclusion The lower PFS of B-treated aNSCLC patients was attributed to an excessive sensitivity of PB in detecting EGFR-mutation. Re-calibration of the technique modified the current percentage of EGFR-mutant and non-analysable samples to 15.5% and 10% of 129, respectively. Periodic monitoring of selected drugs helps to correct protocol defects, to improve quality of treatments, and to reduce costs.

References and/or acknowledgements Conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.